TL;DR
The metabolic drug landscape is shifting toward daily oral formulations as Eli Lilly launches its small-molecule pill, Foundayo, in the UK, while clinical-stage challenger Viking Therapeutics prepares to initiate its own oral Phase 3 trials. Simultaneously, the market-dominant duopoly of Eli Lilly and Novo Nordisk is aggressively defending its commercial territory, winning a landmark antitrust lawsuit against telehealth compounders and clashing in federal court over direct-to-consumer advertising.
The Oral Frontier Intensifies with Small-Molecule Alternatives
The convenience-driven oral GLP-1 market is rapidly heating up as next-generation non-peptide small molecules challenge first-generation peptide tablets.
"The UK is the first country in Europe where Foundayo is now available. We’re pleased that this means there is another oral treatment option for eligible UK patients alongside licensed injectable treatments."
— [oral-glp1-market-competition-lilly-novo
+1] (Source: Reuters)
Unlike Novo's Wegovy tablet, which requires strict fasting, Lilly's daily Foundayo (orforglipron) can be taken at any time with no food or water restrictions [oral-glp1-market-competition-lilly-novo+1]. This user-friendly profile, combined with clinical-stage biotech Viking Therapeutics rapidly advancing its own oral dual agonist VK2735, threatens to disrupt the traditional injectable-dominated landscape by offering patients a highly flexible alternative [viking-therapeutics-vktx-ma-target-oral-vk2735-2026
].
What to watch: Watch whether Viking Therapeutics successfully initiates its Phase 3 clinical trial for the oral tablet formulation of VK2735 in the fourth quarter of 2026 [viking-therapeutics-vktx-ma-target-oral-vk2735-2026].
Courtrooms Become the New Battleground for Market Share
The commercial struggle between the two dominant GLP-1 manufacturers is increasingly fought in federal courtrooms rather than just clinical trials.
"Misleading advertisements that selectively compare lower doses of Novo Nordisk's medicines against higher doses of Lilly’s medicines, based on outdated studies, leave patients with the mistaken impression that Lilly's drugs are vastly superior, and that is simply not true."
— [novo-sues-lilly-false-advertising-glp1-2026
] (Source: MobiHealthNews)
With Lilly capturing 60.9% of the U.S. obesity and diabetes market by revenue compared to Novo's 38.8%, controlling the clinical narrative through direct-to-consumer advertising is a high-stakes commercial lever [novo-sues-lilly-false-advertising-glp1-2026]. Novo's legal push to block Lilly's nationwide campaigns highlights how quickly brand equity can erode when head-to-head trial data is presented selectively to patients and physicians [novo-sues-lilly-false-advertising-glp1-2026].
What to watch: Watch for the pending decision from Judge Zahid N. Quraishi on Novo's motion to immediately halt Eli Lilly's national advertising campaigns for Zepbound and Mounjaro [novo-sues-lilly-false-advertising-glp1-2026].
The Duopoly Shuts Down the Compounding Threat
Brand-name drugmakers are successfully cutting off the supply of cheaper, compounded GLP-1 alternatives through a coordinated regulatory and legal pincer movement.
"Strive Specialities argued that these exclusivity arrangements restricted competition and locked out legally manufactured compounded versions of GLP-1 agents, thereby limiting patient access to cheaper alternatives."
— [fda-compounding-crackdown-503b-glp1-2026
] (Source: MedWatch)
By winning this federal antitrust lawsuit, Novo and Lilly have secured their digital front doors, ensuring that major telehealth platforms remain aligned with branded, FDA-approved products rather than cheaper compounded copies [fda-compounding-crackdown-503b-glp1-2026]. This legal moat, combined with the FDA's systematic phase-out of compounding shortages, is rapidly closing the window for unauthorized generic sellers [fda-compounding-crackdown-503b-glp1-2026].
What to watch: Watch how compounding pharmacies navigate the closing 503B window as the FDA prepares for up to 16 new branded GLP-1 formulations to enter the market by 2029 [fda-compounding-crackdown-503b-glp1-2026].
What surprised us
- The Pricing of Oral Foundayo. At an expected £100 to £120 per month in the UK, Lilly's daily pill is priced significantly cheaper than its own injectable Mounjaro, which costs roughly £330 per month [oral-glp1-market-competition-lilly-novo+1]. This aggressive pricing strategy indicates a willingness to cannibalize injectable sales to capture the oral market early.
- The Telehealth Exclusivity Win. Defeating Strive Specialties' antitrust lawsuit in mid-August 2026 shows that the courts are willing to uphold exclusive brand-telehealth agreements [fda-compounding-crackdown-503b-glp1-2026]. This effectively shuts down a major digital distribution channel for compounded alternatives.
- Viking's Multi-Front Speed. Viking Therapeutics has fully enrolled its subcutaneous Phase 3 trials while simultaneously targeting a Q4 2026 oral Phase 3 launch [viking-therapeutics-vktx-ma-target-oral-vk2735-2026]. Its expansion into amylin agonists with VK3019 shows it is building a broad-spectrum metabolic portfolio rather than relying on a single asset [viking-therapeutics-vktx-ma-target-oral-vk2735-2026].
Open threads worth a vote
[watch] NICE Decision on NHS Coverage for Eli Lilly's Foundayo (orforglipron)](/topics/019e46ac-88a3-731f-aeee-a2d9443452d6#threads)
Since last time
- Promoted — The commercial launch of Eli Lilly’s oral pill, Foundayo, is now a core focus.
- Escalated — The legal battle against compounding has shifted from "black market" enforcement to a high-stakes antitrust/telehealth strategy.
- Unchanged — The Novo Nordisk vs. Eli Lilly advertising litigation continues in federal court; the core arguments remain identical.
- Disappeared — Bariatric surgery displacement trends; Structure Therapeutics (aleniglipron); customs statistics on illicit shipments.
The Oral Frontier Intensifies (Promoted)
The focus of the oral GLP-1 market has shifted from pipeline potential to commercial reality. While Viking Therapeutics continues to advance its oral dual agonist VK2735, the primary development is the launch of Eli Lilly’s Foundayo (orforglipron) in the UK.
"The UK is the first country in Europe where Foundayo is now available. We’re pleased that this means there is another oral treatment option for eligible UK patients alongside licensed injectable treatments."
— [oral-glp1-market-competition-lilly-novo+1] (Source: Reuters)
Unlike previous oral iterations that required strict fasting, Foundayo offers a more flexible dosing profile. This launch, combined with Viking's progress, signals a move toward a more competitive, convenience-driven market.
"During the period, the company continued to prepare for initiation of Phase 3 trials with the oral formulation of VK2735, expected to begin in the fourth quarter of this year."
— [viking-therapeutics-vktx-ma-target-oral-vk2735-2026] (Source: Viking Therapeutics Press Release)
What to watch: Watch whether Viking Therapeutics successfully initiates its Phase 3 clinical trial for the oral tablet formulation of VK2735 in the fourth quarter of 2026 [viking-therapeutics-vktx-ma-target-oral-vk2735-2026].
Courtrooms Become the New Battleground (Unchanged)
The legal standoff between Novo Nordisk and Eli Lilly regarding comparative advertising remains active. Novo continues to challenge Lilly’s use of data comparing maximum-dose tirzepatide against lower, older doses of semaglutide.
"Misleading advertisements that selectively compare lower doses of Novo Nordisk's medicines against higher doses of Lilly’s medicines, based on outdated studies, leave patients with the mistaken impression that Lilly's drugs are vastly superior, and that is simply not true."
— [novo-sues-lilly-false-advertising-glp1-2026] (Source: MobiHealthNews)
With Lilly capturing 60.9% of the U.S. obesity and diabetes market by revenue compared to Novo's 38.8%, this litigation is a critical lever for protecting brand equity [novo-sues-lilly-false-advertising-glp1-2026].
What to watch: Watch for the pending decision from Judge Zahid N. Quraishi on Novo's motion to immediately halt Eli Lilly's national advertising campaigns for Zepbound and Mounjaro [novo-sues-lilly-false-advertising-glp1-2026].
The Duopoly Shuts Down the Compounding Threat (Escalated)
The strategy against unauthorized compounding has evolved from customs interceptions to a successful antitrust legal offensive. By securing favorable court rulings, the duopoly is effectively locking telehealth platforms into branded, FDA-approved ecosystems.
"Strive Specialities argued that these exclusivity arrangements restricted competition and locked out legally manufactured compounded versions of GLP-1 agents, thereby limiting patient access to cheaper alternatives."
— [fda-compounding-crackdown-503b-glp1-2026] (Source: MedWatch)
This legal moat, combined with the FDA's systematic phase-out of compounding shortages, is rapidly closing the window for unauthorized generic sellers [fda-compounding-crackdown-503b-glp1-2026].
What to watch: Watch how compounding pharmacies navigate the closing 503B window as the FDA prepares for up to 16 new branded GLP-1 formulations to enter the market by 2029 [fda-compounding-crackdown-503b-glp1-2026].
What surprised us
- The Pricing of Oral Foundayo. [NEW] At an expected £100 to £120 per month in the UK, Lilly's daily pill is priced significantly cheaper than its own injectable Mounjaro, which costs roughly £330 per month [oral-glp1-market-competition-lilly-novo+1]. This aggressive pricing strategy indicates a willingness to cannibalize injectable sales to capture the oral market early.
- The Telehealth Exclusivity Win. [NEW] Defeating Strive Specialties' antitrust lawsuit in mid-August 2026 shows that the courts are willing to uphold exclusive brand-telehealth agreements [fda-compounding-crackdown-503b-glp1-2026]. This effectively shuts down a major digital distribution channel for compounded alternatives.
- Viking's Multi-Front Speed. [NEW] Viking Therapeutics has fully enrolled its subcutaneous Phase 3 trials while simultaneously targeting a Q4 2026 oral Phase 3 launch [viking-therapeutics-vktx-ma-target-oral-vk2735-2026]. Its expansion into amylin agonists with VK3019 shows it is building a broad-spectrum metabolic portfolio rather than relying on a single asset [viking-therapeutics-vktx-ma-target-oral-vk2735-2026].
Open threads
- Closed: The previous thread regarding the resolution of Lilly's six federal lawsuits against black-market sellers has been absorbed into the "Compounding Threat" section (the antitrust win).
- Open:
[watch] NICE Decision on NHS Coverage for Eli Lilly's Foundayo (orforglipron)](/topics/019e46ac-88a3-731f-aeee-a2d9443452d6#threads)